# PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

> **NCT01445899** · PHASE2 · COMPLETED · sponsor: **Quark Pharmaceuticals** · enrollment: 258 (actual)

## Conditions studied

- Choroidal Neovascularization
- Diabetic Retinopathy
- Diabetic Macular Edema

## Interventions

- **DRUG:** PF-04523655 (Stratum I)
- **DRUG:** ranibizumab
- **DRUG:** PF-04523655 (Stratum II)

## Key facts

- **NCT ID:** NCT01445899
- **Lead sponsor:** Quark Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2015-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445899, "PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01445899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*